

Applicants: Marc Feldmann, et al.
Serial No.: 09/754,004
Filed: January 3, 2001
Page 2

Page 1, lines 8-16:

This application is a continuation of U.S. Application No. 08/690,775, filed August 1, 1996, now U.S. Patent No. 6,270,766, which is a continuation-in-part of U.S. Application No. 08/607,419, filed February 28, 1996, now abandoned, which is a continuation-in-part of International Application No. PCT/GB94/00462, filed March 10, 1994, which is a continuation-in-part of U.S. Application No. 08/403,785, now U.S. Patent No. 5,741,488, which is the U.S. National Phase of International Application No. PCT/GB93/02070, filed October 6, 1993, which is a continuation-in-part of U.S. Application No. 07/958,248, filed October 8, 1992, now abandoned, the teachings of all of which are incorporated herein by reference.

In the Claims:

Please cancel claims 24-28 without prejudice to applicant's right to pursue the subject matter thereof in a continuing application.

Please amend claims 1 and 4 as follows:

A2

1. (Amended) A method for treating or preventing an inflammatory disease in an individual in need thereof comprising co-administering methotrexate and a TNF α antagonist to said individual, in therapeutically effective amounts.
2. A method of Claim 1 wherein said TNF α antagonist and methotrexate are administered simultaneously.

Applicants: Marc Feldmann, et al.
Serial No.: 09/754,004
Filed: January 3, 2001
Page 3

3. A method of Claim 1 wherein said TNF α antagonist and methotrexate are administered sequentially.

A3
4. (Amended) A method of Claim 1 wherein the inflammatory disease is psoriatic arthritis.

5. A method of Claim 4 wherein said TNF α antagonist is administered in multiple doses.

6. A method of Claim 1 wherein said TNF α antagonist prevents or inhibits TNF α synthesis or TNF α release.

11. A method of Claim 5 wherein said TNF α antagonist is an anti-TNF α antibody or antigen-binding fragment thereof.

12. A method of Claim 11 wherein said anti-TNF α antibody or antigen-binding fragment is a chimeric antibody or chimeric fragment, wherein said chimeric antibody or chimeric fragment comprises a non-human variable region specific for TNF α or an antigen-binding portion thereof and a human constant region.

13. A method of Claim 12 wherein said chimeric antibody binds to one or more epitopes included in amino acid residues set forth in SEQ ID NO:1 or SEQ ID NO:2.

14. A method of Claim 13 wherein said chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.

15. A method of Claim 13 wherein said chimeric antibody is monoclonal antibody cA2.